SGLT2 Inhibitors Reduce Kidney Stone Risk in Type 2 Diabetes

Patients with type 2 diabetes treated with SGLT2 inhibitors vs other common diabetes drugs show up to a 31% reduced risk of kidney stone development.

Related Keywords

Massachusetts , United States , Boston , Julie Paik , Division Of Pharmacoepidemiology , Division Of Renal Kidney Medicine At Brigham , Medscape Medical , Urinary Citrate , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm , T2dm , 2d , Kidney Stones , Nephrolithiasis , Renal Calculus , Renal Calculi , Kidneys , Sglt2 Inhibitors , Odium Glucose Transporter 2 Inhibitors , Odium Glucose Co Transporter 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors , Renal Disease , Kidney Disease , Kidney Disorder , Renal Disorder , Ephropathy , Renal Failure ,